Compound information
- Natural Products
- NACP136721
- Molecular Formula
- C18H30O3
- Molecular Weight
- 294.21949482 g/mol
- Structure
-
- IUPAC Name
- 9-oxooctadeca-5,7-dienoic acid
- InChI
- InChI=1S/C18H30O3/c1-2-3-4-5-6-8-11-14-17(19)15-12-9-7-10-13-16-18(20)21/h7,9,12,15H,2-6,8,10-11,13-14,16H2,1H3,(H,20,21)
- InChI Key
- UXONISNZWGFLGH-UHFFFAOYSA-N
- SMILES
- O=C(O)CCCC=CC=CC(=O)CCCCCCCCC
- CAS
- SuperClass
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- SubClass
- Lineolic acids and derivatives
- Source
- CNP0121137
Warheads
- Michael Acceptor
-
ADMET Property
Physicochemical Property
| Property | Value | Property | Value |
|---|---|---|---|
| Heavy Atom Count | 21 | Ring Count | 0 |
| Heteroatom Count | 3 | Rotatable Bond Count | 14 |
| Hydrogen Bond Acceptor Count | 2 | Hydrogen Bond Donor Count | 1 |
| Topological Polar Surface Area | 54.37 Å2 | LogP | 5.233 |
| LogS | -4.081 | LogD | 3.378 |
Absorption
| Property | Value | Property | Value |
|---|---|---|---|
| Pgp inhibitor | 0.124 | Pgp substrate | 0.002 |
| HIA | 0.968 | F20 % | 0.953 |
| F30 % | 0.013 | Caco-2 | -4.69 |
| MDCK | -4.552 |
Distribution
| Property | Value | Property | Value |
|---|---|---|---|
| BBB Penetration | 0.964 | PPB | 87.537 |
| VD | 0.638 | Fu | 1.876 |
Metabolism
| Property | Value | Property | Value |
|---|---|---|---|
| CYP1A2 inhibitor | 0.834 | CYP1A2 substrate | 0.281 |
| CYP2A6 substrate | 0.335 | CYP2B6 substrate | 0.462 |
| CYP2C19 inhibitor | 0.043 | CYP2C19 substrate | 0.298 |
| CYP2C8 substrate | 0.505 | CYP2C9 inhibitor | 0.284 |
| CYP2C9 substrate | 0.026 | CYP2D6 inhibitor | 0.291 |
| CYP2D6 substrate | 0.125 | CYP2E1 substrate | 0.274 |
| CYP3A4 inhibitor | 0.071 | CYP3A4 substrate | 0.021 |
Excretion
| Property | Value | Property | Value |
|---|---|---|---|
| T1/2 | 0.709 | CL | 1.949 |
Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| hERG Blockers | 0.354 | Hepatotoxicity | 0.637 |
| Mutagenicity | 0.01 | Rat Oral Acute Toxicity | 0.016 |
| FDAMDD | 0.559 | Skin Sensitization | 0.997 |
| Carcinogenicity | 0.839 | Eye Corrosion | 0.019 |
| Eye Irritation | 0.936 | Respiratory Toxicity | 0.216 |
Environmental Toxicity
| Property | Value | Property | Value |
|---|---|---|---|
| Bioconcentration Factors | 0.562 | IGC50 | 4.774 |
| LC50FM | 5.231 | LC50DM | 5.688 |
Tox21 Pathway
| Property | Value | Property | Value |
|---|---|---|---|
| NR-AR | 0.239 | NR-AR-LBD | 0.345 |
| NR-AhR | 0.004 | NR-Aromatase | 0.092 |
| NR-ER | 0.225 | NR-ER-LBD | 0.376 |
| NR-PPAR-gamma | 0.919 | SR-ARE | 0.885 |
| SR-ATAD5 | 0.383 | SR-HSE | 0.813 |
| SR-MMP | 0.035 | SR-p53 | 0.6 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.